Neugrastim
Generic Name
Filgrastim
Manufacturer
Reliance Life Sciences
Country
India
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| neugrastim 300 mcg injection | ৳ 2,800.00 | N/A |
Description
Overview of the medicine
Neugrastim is a biosimilar of Filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF). It stimulates the production, maturation, and activation of neutrophils, which are crucial white blood cells involved in fighting infection.
Uses & Indications
Dosage
Adults
5 mcg/kg/day administered as a single daily subcutaneous injection, or intravenous infusion.
Elderly
No specific dose adjustment is recommended for elderly patients.
Renal_impairment
No specific dose adjustment is recommended for patients with renal impairment.
How to Take
Administer by subcutaneous injection or intravenous infusion. Do not shake the pre-filled syringe. Allow to reach room temperature before injection.
Mechanism of Action
Filgrastim binds to specific G-CSF receptors on hematopoietic stem cells, promoting their proliferation and differentiation into mature neutrophils. It also enhances the functional activity of neutrophils, including phagocytosis and cytokine production.
Pharmacokinetics
Onset
Increased neutrophil counts within 24 hours.
Excretion
Primarily renal, but clearance is also dependent on neutrophil mass.
Half life
Approximately 3.5 hours after subcutaneous administration and 2.7 hours after intravenous administration.
Absorption
Rapidly absorbed after subcutaneous administration with peak serum concentrations occurring in 3-5 hours.
Metabolism
Primarily cleared by neutrophil-mediated degradation.
Side Effects
Contraindications
- •Patients with a history of serious allergic reactions to Filgrastim or E. coli-derived proteins.
- •Patients with myeloid leukemia unless administered as part of a chemotherapy regimen to mobilize PBPCs.
Drug Interactions
Lithium
May potentiate the myeloproliferative effects of Filgrastim.
Chemotherapy and radiation
Do not administer Filgrastim in the 24 hours before or after cytotoxic chemotherapy. Avoid concomitant use with radiation therapy.
Storage
Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.
Overdose
Symptoms of overdose include leukocytosis (very high white blood cell count). Management involves discontinuing Filgrastim therapy and monitoring blood cell counts. Supportive care as needed.
Pregnancy & Lactation
Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether Filgrastim is excreted in human milk; caution should be exercised when administered to a nursing woman.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24-36 months, refer to product labeling.
Availability
Hospitals, specialized pharmacies
Approval Status
Approved
Patent Status
Patent expired for original Filgrastim; biosimilar available
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
